This content is from: Home
Davis Polk advises AstraZeneca on $15b spin-off and merger
Pharmaceuticals business AstraZeneca has chosen the same lawyers that worked on its recent merger to advise on the company's next step, a deal valued at $15 billion.
To access our in-house intelligence please request a trial here.
Read this article – and more – for a one-week period.
REQUEST ACCESSAre you already an IFLR subscriber? Login here